Table 1.
Patient and Disease State Characteristics
| Demographics | Results |
|---|---|
| Total episodes | 72 |
| Unique patients, n | 57 |
| Age at admission, median (IQR), yr | 10 (6–13) |
| Sex, male, n (%) | 32 (56)* |
| Weight, median (IQR), kg | 32.2 (18.05–51.4) |
| Race, white, n (%) | 47 (82.4)* |
| Previous history of antifungal therapy for suspected, proven, possible, or probable IFI, n (%) | 26 (45.6)* |
| Underlying malignancy, n (%)* | |
| Acute lymphoblastic leukemia | 20 (35) |
| Acute myeloid leukemia | 11 (19.2) |
| Lymphoma | 12 (21) |
| Aplastic anemia | 5 (8.7) |
| Solid tumor | 5 (8.7) |
| Solid-organ transplant recipient | 4 (7) |
| Underwent stem cell transplantation prior to IFI, n (%) | 12 (15.8) |
| Time between hematologic/oncologic diagnosis or stem cell transplantation and presentation with IFI, median (range), days | 68 (1–3285); average = 225 days |
| Status of underlying disease at time of diagnosis of IFI, n (%)*† | |
| Remission | 36 (54.3) |
| Active | 36 (52.6) |
IFI, invasive fungal infections
* Percentage of unique patients.
† There were 4 unique patients who had multiple combination anti-fungal therapy episodes who received a diagnosis of either active or remission of underlying disease.